Overview

A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation

Status:
Recruiting
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and effectiveness of a once-daily medication, fenofibrate (Lofibra), to prevent ischemic cholangiography (IC) in persons who were transplanted with livers donated after circulatory death (DCD).
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Fenofibrate